ResearcherUniversity of CincinnatiActive in the last 2 years
Paul H. McClelland
Matched on ORCID iD 0000-0002-3119-6531; OpenAlex author ID A5012145850, A5138877714. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2024: 1 paper · 2025: none · 2026: 3 papers
Papers 4
- Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19990-7↗
- ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20039-y↗
- ASO Author Reflections: Looking Beyond Imaging-Multimodal Response Assessment after Modern Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20107-3↗
- Neoadjuvant and Adjuvant Therapy in Resectable Pancreatic Adenocarcinoma. First author DOI 10.1016/j.suc.2024.04.002↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Syed A. Ahmad · 3 shared papers, 2026 · strength 1.16
- Paper ASO Author Reflections: Looking Beyond Imaging-Multimodal Response Assessment after Modern Neoadjuvant Therapy for Panc… DOI 10.1245/s10434-026-20107-3↗
- Paper Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-19990-7↗
- Paper ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Ad… DOI 10.1245/s10434-026-20039-y↗
- Ryan P. Johnson · 3 shared papers, 2024–2026 · strength 0.89
- Paper Neoadjuvant and Adjuvant Therapy in Resectable Pancreatic Adenocarcinoma. DOI 10.1016/j.suc.2024.04.002↗
- Paper Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-19990-7↗
- Paper ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Ad… DOI 10.1245/s10434-026-20039-y↗
- Davendra P. S. Sohal · 2 shared papers, 2026 · strength 0.53
- Paper Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-19990-7↗
- Paper ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Ad… DOI 10.1245/s10434-026-20039-y↗
- Jordan R. Kharofa · 2 shared papers, 2026 · strength 0.53
- Paper Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-19990-7↗
- Paper ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Ad… DOI 10.1245/s10434-026-20039-y↗
- Gregory C. Wilson · 2 shared papers, 2026 · strength 0.53
- Paper Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-19990-7↗
- Paper ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Ad… DOI 10.1245/s10434-026-20039-y↗
- Olugbenga Olanrele Olowokure · 2 shared papers, 2026 · strength 0.53
- Paper Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-19990-7↗
- Paper ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Ad… DOI 10.1245/s10434-026-20039-y↗
- Sameer H. Patel · 2 shared papers, 2026 · strength 0.53
- Paper Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. DOI 10.1245/s10434-026-19990-7↗
- Paper ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Ad… DOI 10.1245/s10434-026-20039-y↗
- Syed Ameen Ahmad · 1 shared paper, 2024 · strength 0.36
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.